Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORP-103
- Development stage
- Preclinical
- Lead developer
- OrphoMed
- Modality
- Small Molecules
01
Overview
ORP-103 is a preclinical small-molecule drug candidate initially developed by OrphoMed for the treatment of gastrointestinal motility disorders within the broader category of digestive system disorders. Publicly available pipeline summaries list the program as focused on functional gastrointestinal indications, but no detailed target, molecular class, or pharmacologic mechanism has been disclosed, and no clinical trial entries or regulatory filings are yet associated with this asset.
Beyond the preview
Go deeper on ORP-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORP-103.